Showing results (191-200 of 203) with videos related to
Sort By:
Pageof 21
European Journal of Cancer (Oxford, England : 1990)|March 10, 2023
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trialFrankie A Holmes, Beverly Moy, Suzette Delaloge, et al.NPJ Breast Cancer|June 25, 2026
Individualised progesterone receptor modulator prevention strategies for triple-negative breast cancer in BRCA1 pathogenic variant carriersMartin Widschwendter, Rita Schmutzler, Nora Pashayan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerMarion T van Mackelenbergh, Sibylle Loibl, Michael Untch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Multifactorial approach to predicting resistance to anthracyclinesChristine Desmedt, Angelo Di Leo, Evandro de Azambuja, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 TherapyPierre Squifflet, Everardo D Saad, Sibylle Loibl, et al.Journal of the National Cancer Institute|December 5, 2021
Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials MethodologyRichard M Goldberg, Richard Adams, Marc Buyse, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system databaseQian Shi, Aimery de Gramont, Axel Grothey, et al.The Lancet. Oncology|February 15, 2016
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialArlene Chan, Suzette Delaloge, Frankie A Holmes, et al.JAMA Network Open|September 21, 2019
Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal CancerTomasz Burzykowski, Elisabeth Coart, Everardo D Saad, et al.Nature Reviews. Clinical Oncology|August 5, 2021
International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancerEmmanouil Fokas, Ane Appelt, Robert Glynne-Jones, et al.Pageof 21